Cutaneous lymphomas and COVID‐19: What is known so far?

The Coronavirus disease 2019 (COVID‐19) pandemic spreads quickly all over the world. There are no sufficient data in the literature about COVID‐19 infection and cutaneous lymphomas. This review sheds the light on what is known so far about COVID‐19 with a cutaneous lymphoma perspective. Cutaneous T‐cell lymphoma (CTCL) diagnosis does not represent a predisposing factor to viral infections and most of CTCL patients have indolent disease. However, physicians should be cautious with patients with aggressive primary cutaneous lymphomas and advanced CTCL. Different treatment strategies for cutaneous lymphomas should be taken into consideration during the COVID‐19 pandemic. Thus, it is highly needed to estimate the benefit‐to‐risk ratio on a case‐by‐case basis. [ABSTRACT FROM AUTHOR]